DK0918795T3 - Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati - Google Patents

Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati

Info

Publication number
DK0918795T3
DK0918795T3 DK98911778T DK98911778T DK0918795T3 DK 0918795 T3 DK0918795 T3 DK 0918795T3 DK 98911778 T DK98911778 T DK 98911778T DK 98911778 T DK98911778 T DK 98911778T DK 0918795 T3 DK0918795 T3 DK 0918795T3
Authority
DK
Denmark
Prior art keywords
arg
ile
gly
thr
val
Prior art date
Application number
DK98911778T
Other languages
English (en)
Inventor
Andrew J Schneider
Jack Henkin
Noel P Bouck
David W Dawson
Original Assignee
Abbott Lab
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab, Univ Northwestern filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0918795T3 publication Critical patent/DK0918795T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98911778T 1997-03-17 1998-03-16 Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati DK0918795T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82066797A 1997-03-17 1997-03-17
PCT/US1998/005327 WO1998041542A1 (en) 1997-03-17 1998-03-16 Antiangiogenic drug to treat cancer, arthritis and retinopathy

Publications (1)

Publication Number Publication Date
DK0918795T3 true DK0918795T3 (da) 2005-03-14

Family

ID=25231427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98911778T DK0918795T3 (da) 1997-03-17 1998-03-16 Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati

Country Status (9)

Country Link
EP (1) EP0918795B1 (da)
JP (2) JP4254972B2 (da)
AT (1) ATE280781T1 (da)
CA (1) CA2255661C (da)
DE (1) DE69827223T2 (da)
DK (1) DK0918795T3 (da)
ES (1) ES2231973T3 (da)
PT (1) PT918795E (da)
WO (1) WO1998041542A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3753612B2 (ja) * 1998-05-22 2006-03-08 アボット・ラボラトリーズ 抗血管新生作用を有するペプチド医薬
US6774211B1 (en) 1998-05-22 2004-08-10 Abbott Laboratories Peptide antiangiogenic drugs
US6716963B1 (en) 1998-05-22 2004-04-06 Abbott Laboratories Peptide antiangiogenic drugs
US6753408B1 (en) 1999-11-22 2004-06-22 Fortuna Haviv Peptides having antiangiogenic activity
DK1232183T3 (da) * 1999-11-22 2006-05-29 Abbott Lab Peptider, som har antiangiogen aktivitet
US6777535B1 (en) 1999-11-22 2004-08-17 Abbott Laboratories N-alkylated peptides having antiangiogenic activity
CO5261544A1 (es) * 1999-11-22 2003-03-31 Abbott Lab Peptidos n-alquilados que tienen actividad antiangiogenica
US20020183242A1 (en) * 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
US20030119746A1 (en) * 2001-10-31 2003-06-26 Fortuna Haviv Hepta-and octapeptides having antiangiogenic activity
CN1314705C (zh) * 2005-06-03 2007-05-09 中国药科大学 高效抑制血管生成多肽及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200397A (en) * 1990-02-22 1993-04-06 W. R. Grace & Co.-Conn. Use of peptide analogs of thrombospondin for the inhibition of angiogenic activity
WO1993016716A1 (en) * 1992-02-24 1993-09-02 Northwestern University Method and composition for inhibiting angiogenesis
AU697624B2 (en) * 1993-08-13 1998-10-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions for stimulating and inhibiting TGF-beta activity

Also Published As

Publication number Publication date
JP2001506671A (ja) 2001-05-22
EP0918795A1 (en) 1999-06-02
DE69827223T2 (de) 2006-02-02
EP0918795B1 (en) 2004-10-27
JP2009001576A (ja) 2009-01-08
CA2255661A1 (en) 1998-09-24
ATE280781T1 (de) 2004-11-15
ES2231973T3 (es) 2005-05-16
JP4254972B2 (ja) 2009-04-15
PT918795E (pt) 2005-02-28
CA2255661C (en) 2004-08-10
WO1998041542A1 (en) 1998-09-24
DE69827223D1 (de) 2004-12-02

Similar Documents

Publication Publication Date Title
US5229489A (en) Parathyroid hormone antagonists
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
GB9720054D0 (en) Biological products
EP0254080A3 (en) Malonic acid derivatives and methods for their synthesis
ATE458054T1 (de) Menschliches parathyroidhormon, modifikationen, herstellung und verwendung
CZ20022740A3 (cs) Sloučenina, způsob přípravy sloučeniny, farmaceutický prostředek a způsob léčení rakoviny
DK0479912T3 (da) Fremgangsmåde til hæmning af N-endereglens forløb i levende celler
Chen et al. Synthesis and pharmacology of novel analogues of oxytocin and deaminooxytocin: directed methods for the construction of disulfide and trisulfide bridges in peptides
EP0597997B1 (en) Lanthionine bridged peptides
PT918795E (pt) Droga antiangiogenica para tratar cancro artrite e retinopatia
AU5362190A (en) Novel peptides, and antidementia agents containing the same
DE69836428D1 (de) Karzinostatische wirkstoffe
DE69530404D1 (de) Analogen des keratinozytenwachstumfaktors
ATE242202T1 (de) Peptide
EP0581429A2 (en) Process for synthesizing cyclic depsipeptides
Schmittberger et al. Synthesis of the palmitoylated and prenylated C-terminal lipopeptides of the human R-and N-Ras proteins
Ding et al. Structure–activity relationships of side-chain modified didemnins
US6268339B1 (en) Lanthionine bridged peptides
Turner et al. Synthesis of novel amino acid carbohydrate hybrids via Mitsunobu glycosylation of nitrobenzenesulfonamides
Sai et al. Intestinal absorption of fluorescence-derivatized cationic peptide 001-C8-NBD via adsorptive-mediated transcytosis
WO1997010262A1 (fr) Derives peptidiques
Boyer et al. Critical role of an amino acid residue in a T cell determinant is due to its interaction with a neighboring non‐critical residue
Borsuk et al. Application of substituted 2-(trimethylsilyl) ethyl esters to suppress diketopiperazine formation
NZ508812A (en) Peptides for the prevention or treatment of HIV
Spatola Synthesis of pseudopeptides